(NASDAQ: HCM) Hutchmed's forecast annual revenue growth rate of 12.99% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.21%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.24%.
Hutchmed's revenue in 2025 is $630,201,000.On average, 3 Wall Street analysts forecast HCM's revenue for 2025 to be $577,461,001,869, with the lowest HCM revenue forecast at $495,496,506,497, and the highest HCM revenue forecast at $640,015,812,457. On average, 3 Wall Street analysts forecast HCM's revenue for 2026 to be $648,120,831,040, with the lowest HCM revenue forecast at $514,244,646,050, and the highest HCM revenue forecast at $730,485,391,315.
In 2027, HCM is forecast to generate $836,562,730,981 in revenue, with the lowest revenue forecast at $836,562,730,981 and the highest revenue forecast at $836,562,730,981.